Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02360579 · ClinicalTrials.gov registry record · Phase 2
Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma
A Phase 2 study, sponsored by Iovance Biotherapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
NCT02360579 is a Phase 2 study that has completed, run by Iovance Biotherapeutics. The registered enrollment target is 220 participants.
The verdict
NCT02360579, a Phase 2 study, has completed, sponsored by Iovance Biotherapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
Study Summary
Prospective, interventional multicenter study evaluating adoptive cell therapy (ACT) via infusion of LN-144 (autologous TIL) followed by interleukin 2 (IL-2) after a nonmyeloablative lymphodepletion (NMA LD) preconditioning regimen.
Interventions
- BIOLOGICAL Lifileucel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2015-09-24 |
| Est. Completion | 2024-10-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02360579
The ClinicalTrials.gov registry entry for NCT02360579 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Iovance Biotherapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lifileucel is the first listed.
NCT02360579 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02360579 about?
NCT02360579 is a clinical study titled "Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma". Prospective, interventional multicenter study evaluating adoptive cell therapy (ACT) via infusion of LN-144 (autologous TIL) followed by interleukin 2 (IL-2) after a nonmyeloablative lymphodepletion (NMA LD) preconditioning regimen.
What is the current status of trial NCT02360579?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2015-09-24. Estimated completion is 2024-10-24.
What interventions are being tested in trial NCT02360579?
The interventions under investigation include: Lifileucel (BIOLOGICAL).
Who is sponsoring clinical trial NCT02360579?
This trial is sponsored by Iovance Biotherapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.